J Cell Mol Med, Microbial Biotechnology join Wiley Open Access publishing program

NewsGuard 100/100 Score

John Wiley & Sons, Inc., announced today that Journal of Cellular and Molecular Medicine and Microbial Biotechnology have joined the Wiley Open Access publishing program. All articles in these two journals are now open access and free to view, download and share.

Since its launch in 1996, Journal of Cellular and Molecular Medicine has attracted very high quality submissions and attained an Impact Factor of 4.125, placing it 22nd in the Medicine Research and Experimental ISI Category. With its emphasis on translational medicine, and high quality review series, Journal of Cellular and Molecular Medicine is of interest to a wide spectrum of researchers and clinicians. Converting to open access allows all readers to benefit from the high-level research advances reported in the journal, driving biomedical research forward and accelerating discovery.

"We are excited that Journal of Cellular and Molecular Medicine is joining the Wiley Open Access publishing program, as it will make the highly topical and well-regarded review series commissioned by our Editor-in-Chief, Professor LM Popescu, available to all," said Dr. Jo Wixon, Senior Editor, Health Sciences, Wiley.

Since its inception, Microbial Biotechnology has published papers of original research reporting significant advances in any aspect of microbial applications to biotechnologies, making it of interest to a wide spectrum of researchers across the scope of both Microbiology and Biotechnology. Converting to open access will significantly benefit readers and researchers in the field of biotechnology, through the dissemination of high quality research from Microbial Biotechnology.

"The Society for Applied Microbiology is delighted that this change is taking place. Enabling readers to access the contents of this already successful journal free of charge will foster progress in this important area of applied microbiology," said Society for Applied Microbiology (SfAM) President, Professor Martin Adams.

"Last year Wiley successfully converted EMBO Molecular Medicine and Evolutionary Applications to open access from a subscription model. With this experience we are confident that these well-established journals will continue to thrive as they join our program of fully open access journals," said Rachel Burley, Vice President and Director, Open Access, Wiley. "The Wiley Open Access program's promise of quality is being realized as we now have four journals with Impact Factors; Ecology and Evolution is set to get its first Impact Factor this summer; and MicrobiologyOpen and Journal of the American Heart Association have both recently been accepted for Indexing in MEDLINE."

Journal of Cellular and Molecular Medicine and Microbial Biotechnology will publish all from January 2013 under the Creative Commons Attribution (CC-BY) License, which permits use, distribution, reproduction and adaptation in any medium, provided the original work is properly cited. A publication fee will be payable by authors or their funder on acceptance of their primary research articles. Authors affiliated with, or funded by, an organization that has a Wiley Open Access Account can publish without directly paying any publication charges.

Source: Wiley

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Triple-negative breast cancer patients with high immune cell levels have lower relapse risk after surgery